JP2009539353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539353A5 JP2009539353A5 JP2009513483A JP2009513483A JP2009539353A5 JP 2009539353 A5 JP2009539353 A5 JP 2009539353A5 JP 2009513483 A JP2009513483 A JP 2009513483A JP 2009513483 A JP2009513483 A JP 2009513483A JP 2009539353 A5 JP2009539353 A5 JP 2009539353A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- antigen
- clade
- consensus
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 125000002796 nucleotidyl group Chemical group 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 101710177291 Gag polyprotein Proteins 0.000 claims 1
- 102100034353 Integrase Human genes 0.000 claims 1
- 101710125418 Major capsid protein Proteins 0.000 claims 1
- 101710192141 Protein Nef Proteins 0.000 claims 1
- 108010078428 env Gene Products Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 108010089520 pol Gene Products Proteins 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81081606P | 2006-06-02 | 2006-06-02 | |
| PCT/US2007/070321 WO2007143606A2 (en) | 2006-06-02 | 2007-06-04 | Hiv-1 clade a consensus sequences, antigens, and transgenes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009539353A JP2009539353A (ja) | 2009-11-19 |
| JP2009539353A5 true JP2009539353A5 (https=) | 2011-07-28 |
Family
ID=38802278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009513483A Withdrawn JP2009539353A (ja) | 2006-06-02 | 2007-06-04 | Ｈｉｖ−１クレイドａのコンセンサス配列、抗原及びトランス遺伝子 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8119144B2 (https=) |
| EP (2) | EP2399602B1 (https=) |
| JP (1) | JP2009539353A (https=) |
| AU (1) | AU2007256717B2 (https=) |
| CA (1) | CA2654324A1 (https=) |
| DK (2) | DK2029168T3 (https=) |
| ES (2) | ES2396915T3 (https=) |
| WO (1) | WO2007143606A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9238679B2 (en) * | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
| US20160256539A1 (en) * | 2013-11-14 | 2016-09-08 | The Trustees Of The University Of Pennsylvania | HIV-1 ENV DNA Vaccine Plus Protein Boost Delivered by EP Expands B- and T-Cell Response and Neutralizing |
| KR20240137107A (ko) | 2019-07-16 | 2024-09-19 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| US6780407B1 (en) | 1989-03-08 | 2004-08-24 | Aventis Pasteur | Pox virus comprising DNA sequences encoding CEA and B7 antigen |
| US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
| US6277558B1 (en) | 1990-11-30 | 2001-08-21 | Kansas University Medical Center | α-3 chain type IV collagen polynucleotides |
| US5650398A (en) | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
| PT799058E (pt) | 1994-12-24 | 2003-11-28 | Univ Cambridge Tech | Melhoramentos na funcao endometrica ou com ela relacionados |
| US6156567A (en) | 1996-07-03 | 2000-12-05 | Merial | Truncated transcriptionally active cytomegalovirus promoters |
| US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
| US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| US20020136722A1 (en) | 1997-06-18 | 2002-09-26 | Heath Andrew William | Vaccination method |
| CA2302522C (en) | 1997-08-29 | 2010-08-17 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| AU784679B2 (en) | 1999-12-23 | 2006-05-25 | International Aids Vaccine Initiative | Improvements in or relating to immune responses to HIV |
| JP2004507231A (ja) | 2000-06-15 | 2004-03-11 | アメリカ合衆国 | 免疫応答を向上させるための、ｇｍ−ｃｓｆを発現する組換え非−複製性ウィルスおよびその使用 |
| IT1318103B1 (it) | 2000-07-03 | 2003-07-23 | Nuovo Pignone Spa | Sistema di connessione tra un ugello di bassa pressione ed untransition duct in una turbina a gas |
| BRPI0414443A (pt) * | 2003-09-17 | 2006-11-21 | Univ Duke | imunógenos consensuais/ancestrais |
| WO2005047483A2 (en) * | 2003-11-12 | 2005-05-26 | Medical Research Council | Renta: an hiv immunogen and uses thereof |
-
2007
- 2007-06-04 DK DK07798067.0T patent/DK2029168T3/da active
- 2007-06-04 ES ES07798067T patent/ES2396915T3/es active Active
- 2007-06-04 CA CA002654324A patent/CA2654324A1/en not_active Abandoned
- 2007-06-04 ES ES11005764.3T patent/ES2528951T3/es active Active
- 2007-06-04 JP JP2009513483A patent/JP2009539353A/ja not_active Withdrawn
- 2007-06-04 DK DK11005764.3T patent/DK2399602T3/en active
- 2007-06-04 US US11/757,550 patent/US8119144B2/en active Active
- 2007-06-04 EP EP11005764.3A patent/EP2399602B1/en not_active Not-in-force
- 2007-06-04 EP EP07798067A patent/EP2029168B1/en not_active Not-in-force
- 2007-06-04 AU AU2007256717A patent/AU2007256717B2/en not_active Ceased
- 2007-06-04 WO PCT/US2007/070321 patent/WO2007143606A2/en not_active Ceased
-
2012
- 2012-02-17 US US13/398,897 patent/US8735542B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alizadeh et al. | Designing a novel multi‑epitope vaccine against Ebola virus using reverse vaccinology approach | |
| Medhekar et al. | Diversity-generating retroelements | |
| Marston et al. | Comparative analysis of the full genome sequence of European bat lyssavirus type 1 and type 2 with other lyssaviruses and evidence for a conserved transcription termination and polyadenylation motif in the G–L 3′ non-translated region | |
| Emonet et al. | Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies | |
| Shum et al. | Aptamer-based therapeutics: new approaches to combat human viral diseases | |
| US12269846B2 (en) | CoV-2 (CoV-n) antibody neutralizing and CTL vaccines using protein scaffolds and molecular evolution | |
| Malherbe et al. | Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies | |
| JP2012095652A5 (https=) | ||
| JP2019525914A5 (https=) | ||
| JP2010535495A5 (https=) | ||
| JP2011087580A5 (https=) | ||
| JP2014507146A5 (https=) | ||
| JP2009539353A5 (https=) | ||
| Fenimore et al. | Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage | |
| Hastie et al. | The Arenaviridae family: knowledge gaps, animal models, countermeasures, and prototype pathogens | |
| JP2019522626A5 (https=) | ||
| Patel et al. | Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins | |
| Oxford et al. | Human virology | |
| JP2010532656A5 (https=) | ||
| Dehghani et al. | Functional and structural characterization of Ebola virus glycoprotein (1976–2015)—An in silico study | |
| Parvege et al. | Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus | |
| Aditham et al. | Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations | |
| CN101531719B (zh) | 一种禽流感基因工程多肽抗原 | |
| Carrillo | Foot and mouth disease virus genome | |
| Nazneen Akhand et al. | Genome based evolutionary study of SARS-CoV-2 towards the prediction of epitope based chimeric vaccine |